$KPTI Commercial stage oncology player, targeting nuclear export in cancer. 1 wholly owned FDA approved drug XPOVIO (selinexor-SELective Inhibitor of NUclear EXport, given ORally, once or twice a week) in 2 indications: RRMM (3th/4th line 2019/07) and RR DLBCL (3rd line 2020/06).
$KPTI Net sales $65M in first year.  Watch out for PDUFA 19 March 2021 XPOVIO in 2nd line RMM - will increase patent population by factor 5! Estimated peak revenue $750M to $1B. Market cap $1.182M. Price $16.09. Cash $348M, runway into middle of 2022. Oncology is a hot M&A space.
$KPTI interesting moves
$KPTI Again a nice volume driven spike. Something's happening here...
$KPTI Nice press release here: positive Ph3 SEAL study, good growth in Xpovio product sales and looking forward to PDUFA action date of 19 March 21 for second line MM. If approved, will boost Xpovio sales.
$KPTI sounds good. Now patiently waiting on a +$30 stock price😴
$KPTI sounds good. Now patiently waiting on a +$30 stock price
$KPTI sounds good. Now patiently waiting on a +$30 stock price
$KPTI early approval
You can follow @SDegrijse.
Tip: mention @twtextapp on a Twitter thread with the keyword “unroll” to get a link to it.

Latest Threads Unrolled:
Those who think consciousness raising & movement building are disconnected, or even a distraction from electoral politics have not paid attention to the history of social change.In this thread, we
Read more
The 2020s will be known as the Remote Work decadeA few predictions of what is likely to emerge[ a thread ] Third Space: Office and Working from Home will
Read more
1/29: Have you ever had a concept explained to you that helps frame complex issues you’ve been wrestling with and opens your eyes to new possibilities? A concept that I
Read more
By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.